Circulating and Disseminated Tumor Cells in Advanced Prostate Cancer Management
Author Information
Author(s): Stephan Kruck, Georgios Gakis, Arnulf Stenzl
Primary Institution: Eberhard-Karls University
Hypothesis
The presence of circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) is an important determinant for successful treatment in prostate cancer.
Conclusion
Advanced technologies for detecting CTCs and DTCs have the potential to improve the management of advanced prostate cancer, but further studies are needed before they can be standard practice.
Supporting Evidence
- CTCs can be found at high frequency in metastatic prostate cancer, indicating their potential as surrogate markers for clinical outcomes.
- Detection of CTCs has shown significant correlations with established disease indicators like PSA.
- Advanced detection methods like the CTC-chip have demonstrated higher sensitivity and specificity compared to traditional methods.
Takeaway
Doctors are trying to find tiny cancer cells in the blood of prostate cancer patients to help them get better treatment.
Methodology
The study reviews various detection methods for CTCs and DTCs, including immunomagnetic procedures and PCR-based techniques.
Limitations
The clinical applicability of many detection techniques is limited due to complexity and lack of standardization.
Participant Demographics
The study includes advanced prostate cancer patients, with a focus on those with metastatic disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website